PUBLIC COMPANY
save$LYELLyell Immunopharma, Inc.
$LYELSouth San Francisco, CA, USupdated 18d ago
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Phase 11Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2LYL273 for Patients With Relapsed or Refractory mCRC
- phase3A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- phase2Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- —A Biomarker Screening Protocol for Participants With Solid Tumors
- phase1A Study to Investigate LYL845 in Adults With Solid Tumors
- phase1A Study to Investigate LYL797 in Adults With Solid Tumors
- phase2A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)
Insider activity
source: SEC Form 4open-market buys + sells
routine RSU / option mechanics (1)
- Mar 9, 26grantShah Smital · Chief Fin. and Bus. Officer140,000 sh
🐶 Hiring Signal
Where Lyell Immunopharma, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.
therapeutic areaOncology 6
News
no news has mentioned this company yet
Data sources
last refreshed 3m ago
Found something off?
comments(0)
5-min edit window · permanent after that